NovoCure Limited Announces Retirement of Director Timothy Scannell
PUBLIC · NVCRSep 09, 2026
Position
Director
Company
Novocure
Timothy Scannell
ZugBiotechnologyHealth CareMedicalTherapeutics
Description
NovoCure Limited has announced that Timothy Scannell has retired from his position as a director on the company's Board effective September 2, 2026. His retirement comes after five years of service and was not due to any disagreement with the company or its management. The company appreciates his contributions during his tenure
Who to call at Novocure, and when
A new leader at Novocure brings new priorities and often new vendors. The first weeks are when they listen.
An alert the day Novocure raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Novocure, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Novocure. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Novocure
Location
Zug, Zug, Switzerland
About
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. Novocure has ongoing or completed clinical studies investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Novocure changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
ZugBiotechnologyHealth CareMedicalTherapeutics